Radiopharma dose varies globally for pediatric exams
While there are guidelines for recommended radiopharmaceutical doses for pediatric nuclear medicine patients, there is still wide variability around the world in terms of how those standards are followed, according to a new report published online March 31 in the Journal of Nuclear Medicine. {read more here}
A fever of unknown origin (FUO) is characterized by a fever of more than 38 C that lasts two or more weeks and whose cause is unclear despite repeated out-patient tests. Utilizing PET (positron emission tomography) scans typically used in cancer screening, experimental medical research is being carried out at 17 facilities nationwide to identify the cause of such fevers early on, so appropriate treatment can be provided. {read more here}
The investigational PET contrast agent for myocardial perfusion imaging (MPI), flurpiridaz F 18, was found to be superior to MPI with SPECT for assessing coronary artery disease (CAD) in obese patients. The findings were presented yesterday by Lantheus at the American College of Cardiology’s annual scientific session in Chicago. {read more here}
[18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with dual-time-point imaging was accurate in diagnosing breast cancer recurrence with only a small number of false-positive cases, a study published in the Journal of Clinical Oncology has shown. {read more here}